

Product Development Pipeline



		Preclinical	Phase 1	Phase 2	Phase 3	Market
Cognitive Disorders						
ADHD	AZD3480 (TC-1734)				AstraZeneca	
Alzheimer's Disease [†]	AZD1446 (TC-6683)				AstraZeneca	
AZ Research Program (completed)	TBA				AstraZeneca	
Cognitive Dysfunction in Schizophrenia [†]	TC-5619*					
Depression / Anxiety Disorders						
Major Depressive Disorder	TC-5214				AstraZeneca	
Depression / Anxiety Disorder	TC-5685					
Inflammation / Pain						
	TC-6987					
Smoking Cessation / Parkinson's Disease	**	TBA				
Addiction / Obesity	**	TBD				

[†] or one or more other conditions characterized by cognitive impairment
 * AstraZeneca has right to obtain a global license at clinical proof of concept.
 ** GlaxoSmithKline has right to obtain a global license at clinical proof of concept.

January 6, 2010